Biogen Idec Inc (BIIB)

BIIB (NASDAQ:Drugs)
$360.67
pos +0.00
+0.00%
Today's Range: 343.06 - 361.93 | BIIB Avg Daily Volume: 1,643,700
Last Update: 12/19/14 - 3:59 PM EST
Volume: 0
YTD Performance: 29.01%
Open: $0.00
Previous Close: $353.70
52 Week Range: $270.62 - $361.93
Oustanding Shares: 236,155,407
Market Cap: 83,528,167,456
6-Month Chart
TheStreet Ratings Grade for BIIB
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 10 10 11
Moderate Buy 1 1 1 1
Hold 5 5 6 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.65 1.69 1.76 1.65
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 33.49
Price Earnings Comparisons:
BIIB Sector Avg. S&P 500
33.49 33.50 25.85
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
9.55% 30.11% 227.91%
GROWTH 12 Mo 3 Yr CAGR
Revenue 32.60 0.47 0.14
Net Income 34.90 1.07 0.27
EPS 35.80 0.97 0.25
Earnings for BIIB:
EBITDA 1.90B
Revenue 5.81B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $3.74 $3.83 $13.47 $16.67
Number of Analysts 2 1 2 2
High Estimate $3.79 $3.83 $13.51 $16.77
Low Estimate $3.69 $3.83 $13.42 $16.56
Prior Year $2.33 $2.45 $8.93 $13.47
Growth Rate (Year over Year) 60.52% 56.33% 50.78% 23.77%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Dec 19, 2014 | 7:16 PM EST

There had been no catalysts.

By

Jim Cramer

 | Dec 15, 2014 | 7:08 AM EST

Reams of stocks make sense on a pullback. And what looks bad? Anything even remotely connected to oil and gas.

By

Jim Cramer

 | Dec 8, 2014 | 5:08 AM EST

A litany of reasons why you should calm your nerves.

By

Jim Cramer

 | Dec 3, 2014 | 3:59 PM EST

An immense market rotation is happening.

By

Jim Cramer

 | Dec 2, 2014 | 11:38 AM EST

In this era of turmoil, investors can take comfort in this sector.

By

Jim Cramer

 | Nov 14, 2014 | 6:31 PM EST

It's amazing how stupid the market really is.

By

Jim Cramer

 | Oct 30, 2014 | 2:31 PM EDT

Still, it's a good time to review what's happening, so we never forget.

By

Kate Stalter

 | Oct 30, 2014 | 2:00 PM EDT

Some growth leaders in the sector are getting technical support.

bearishBiogen Idec numbers cut at Nomura

Oct 23, 2014 | 6:43 AM EDT

Shares of BIIB now seen reaching $407, according to Nomura. Estimates also reduced, as Avonex is facing increased competition. Buy rating. 

By

Dick Arms

 | Sep 25, 2014 | 7:00 AM EDT

Use one short and one buy.

3 insiders sold a total of 518,620 Starbucks (SBUX) shares for proceeds of $43.449 MM. 4 i...
Yum Brands saw both insider buying and selling reported last week. One insider bought 10,0...

The bearish star cluster on the Starbucks (SBUX) chart that I...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.